补肾方药对骨质疏松大鼠骨中LIM矿化蛋白1表达的影响  

Effects of a Chinese traditional kidney-tonifying compound on expression of LIM mineralization protein in osteoporotic rat bone

作　　者：刘素彩[1] 李桃[2] 李恩[1] 

机构地区：[1]河北医科大学生物化学教研室,石家庄050017 [2]河北医科大学附属第三医院骨科研究所,石家庄050017

出　　处：《中国骨质疏松杂志》2001年第1期72-75,共4页Chinese Journal of Osteoporosis

摘　　要：目的　探讨补肾方药预防糖皮质激素诱导大鼠骨质疏松发生的机理。方法　通过肌肉注射地塞米松造成骨质疏松模型 ,观察补肾中药对骨密度的影响 ,从骨骼中提取mRNA ,采用RT PCR方法对LIM矿化蛋白 (LMP 1)进行半定量。结果　病理组大鼠的骨密度及骨骼中LMP 1的表达明显降低 (P <0 0 5 ) ,而补肾方药组的骨密度及LMP 1的表达明显高于地塞米松组 (P <0 0 5 )。结论　地塞米松抑制LMP 1在骨骼的表达 ,而补肾方药可通过提高LMP 1在骨的表达而预防骨质疏松的发生。Objective\ To study the mechanism by which a traditional Chinese kidney tonifying compound prevents dexamethasone\|induced osteoporosis. Methods\ 36 Wistar rats were divided into three groups:control group was injected with 0\^9% sodium chloride solution,dexamethasone group(DEX) and traditional Chinese medicine group(TCM) were injected with dexamethasone(0\^1 mg/100 g weight)twice a week.TCM group was given kidney\|tonifying compound(0\^32 g/100 g weight)at the same time.After 12 weeks the rats were killed and the total mRNA was extracted from the bone.The expression of LMP\|1 was semi\|quantified by RT\|PCR. Results\ The bone mineral density and the expression of LMP\|1 of the rats in DEX group decreased significantly and those of the rats in TCM group did not decrease. Conclusion\ Traditional Chinese kidney\|tonifying medicine prevents dexamethasone\|induced osteoporosis by up\|regulating expression of LMP\|1.\;

关 键 词：地塞米松 LMP-1mRNA 骨质疏松 补肾方药 

分 类 号：R681.05[医药卫生—骨科学]